Holen Sie sich die Stockscreener-App
0.761
1.68%
-0.0121
Schlusskurs vom Vortag:
$0.773
Offen:
$0.81
24-Stunden-Volumen:
580.35K
Relative Volume:
0.92
Marktkapitalisierung:
$37.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.31M
KGV:
-2.8769
EPS:
-0.2645
Netto-Cashflow:
$-21.07M
1W Leistung:
+12.78%
1M Leistung:
+123.53%
6M Leistung:
-16.83%
1J Leistung:
-23.63%
1-Tages-Spanne:
$0.75
$0.81
1-Wochen-Bereich:
$0.66
$0.81
52-Wochen-Spanne:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ONCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.7588 | 37.93M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.46 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.45 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.48 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.70 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - PR Newswire
Oncolytics names Jared Kelly as CEO - MSN
Oncolytics Biotech stock takes off after naming new CEO - MSN
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation - PR Newswire
Oncolytics (ONCY) Names Jared Kelly as New CEO and Board Member - GuruFocus
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immu - GuruFocus
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences - GlobeNewswire
Oncolytics Biotech stock takes off after naming new CEO | 2025-06-11 | Investing News - Stockhouse
Oncolytics Biotech Inc. - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc. - Barchart.com
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech (ONCY) Appoints New CEO, Jared Kelly - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Appoints New CEO to Drive Immunotherapy Advancements - TipRanks
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs | ONCY Stock News - GuruFocus
Oncolytics Biotech Taps $2B J&J Deal Architect as CEO, Accelerating Fast Track Cancer Programs - Stock Titan
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference - ACCESS Newswire
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - The Globe and Mail
(ONC) Market Dynamics and Trading Signals (ONC:CA) - news.stocktradersdaily.com
(ONC) Proactive Strategies (ONC:CA) - news.stocktradersdaily.com
Against the rise of early onset cancer: a Mugglehead roundup - Mugglehead Magazine
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
(ONC) Advanced Equity Analysis (ONC:CA) - news.stocktradersdaily.com
HC Wainwright Has Pessimistic Outlook of TSE:ONC Q2 Earnings - Defense World
Stocks In Play - Baystreet.ca
Q2 EPS Forecast for Oncolytics Biotech Reduced by Analyst - Defense World
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Dow slumps 460 points, or 1.1%, in early trading following Trump's latest tariff threats targeting Europe and Apple - The Globe and Mail
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - marketscreener.com
Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics (ONCY) Unveils Promising Phase I/II Clinical Trial Da - GuruFocus
Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities | ONCY Stock News - GuruFocus
Oncolytics Brief: Presenting New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - marketscreener.com
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities - PR Newswire
HC Wainwright Issues Negative Outlook for TSE:ONC Earnings - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
(ONC) Strategic Market Analysis (ONC:CA) - news.stocktradersdaily.com
ONCY: Analyst Reiterates Buy Rating with $5.00 Price Target | ONCY Stock News - GuruFocus
Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Price Target at $4.33 - Defense World
Oncolytic Virus Therapy Market Detailed In New Research Report - openPR.com
Jones Trading Reaffirms “Hold” Rating for Oncolytics Biotech (NASDAQ:ONCY) - Defense World
Options Volatility and Implied Earnings Moves Today, May 16, 2025 - The Globe and Mail
(ONC) Market Performance Analysis (ONC:CA) - news.stocktradersdaily.com
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):